International Conference & Exhibition on Tissue Preservation and Biobanking (Biobanking -2015) is scheduled from July 20-22, 2015 in Barcelona, Spain which aims to gather the most elegant societies and industries along with the renowned and honorable persons form top universities across the globe. Biobanking -2015 on behalf of its organizing Committee welcomes all the stem cell technologists, researchers, industrialists, young scientists as well as student and corporate delegates to participate and to have a great experience. The theme of the conference of Biobanking is based on “Emerging Trends for Tissue Preservation for Sustainable Development”. During Biobanking conferences, the International symposiums, B2B meetings, international workshops will also be organized to discuss the specific topics in the field of Stem cell technology. The conference also welcomes International exhibitions form corporate sectors to showcase the recent advancements in the tools and techniques.

Registration Deadline: July 20, 2015

OMICS International is one of the leading Open Access scientific publication group taking initiative and is committed to make genuine and reliable contributions to the world’s scientific community. OMICS International hosts 350 Open Access journals with over 3.5 million readers and the renown and success of the same can be attributed to the strong editorial board which contains over 30000 eminent personalities. OMICS International Congress serve as a bridge between researchers from academia and industry enhanced by its well organized scientific sessions, plenary lectures, poster presentations, world class exhibitions, diverse International Symposiums, highly enriched International Workshops and B2B meetings.

 

Biobank

A biobank is a type of biorepository that stores biological samples (usually human) for use in research. Since the late 1990s biobanks have become an important resource in medical research, supporting many types of contemporary research like genomics and personalized medicine. Biobanks give researchers access to data representing larger numbers of people than could be analyzed previously. Furthermore, samples in biobanks and the data derived from those samples can often be used by multiple researchers for multiple purposes Many diseases are associated with single-nucleotide polymorphisms, and using genome-wide association studies to study such biomarkers is often a goal of biobank research. Large collections of samples representing tens or hundreds of thousands of individuals are necessary to conduct these kinds of studies, so researchers may perform such studies only with large numbers of samples. Many researchers struggled to acquire sufficient samples prior to the advent of biobanks. Biobanks have provoked questions on research ethics and medical ethics, and have provoked widespread discussion. While viewpoints on what constitutes appropriate biobank ethics diverge, consensus has been reached that operating biobanks without establishing carefully considered governing principles and policies could be detrimental to communities that participate in biobank programs.

Human Cancer Biobank

The Cancer Human Biobank (caHUB) is a BBRB derived program that carries out specialized biospecimen and data procurements to support biospecimen science activities. The caHUB network consists of the following components:

·         Biospecimen Source Sites (BSSs) are organizations, such as academic medical centers, rapid autopsy centers, and organ procurement organizations, that obtain patient consent, acquire specimens, and ship them to one of a number of program sites.

The Comprehensive Biospecimen Resource (CBR) is a centralized site that assembles collection and shipping kits, receives most biospecimens from the BSSs for processing and storage, and ships biospecimens from the BSSs to the processing and analysis facilities. The CBR also generates H&E sections from FFPE blocks and produces digital images of these sections.

The Comprehensive Data Resource (CDR) is a centralized data storage facility that obtains patient and specimen data from BSSs and other program sites that handle and analyze samples.

The Pathology Resource Center (PRC) is a network of board certified pathologists who review H&E sections from caHUB collected specimens as a quality control measure and also provide technical direction for caHUB biospecimen collections.

Molecular Analysis Facilities (MAFs) carry out molecular analysis on caHUB collected specimens. MAFs can be individuals or organizations from government, academia, or private industry entities.

Every year over 140,000 new cancer cases are diagnosed in the state of Texas resulting in approximately 40,000 deaths. The probability of effective treatment with a targeted therapeutic can be improved for patients with defined genotypes

Specimens were collected according to the TCRB Standard Operating Procedures to ensure the highest quality tissues. Specimens were first characterized by a TCRB pathologist. Tissues were also processed for DNA/RNA isolation & sequencing, tissue storage and xenograft/cell line derivation. Data from the specimens, their DNA/RNA sequence, and limited clinical information were linked together in TCRB's Acquire database.

Cryopreservation

A process where cells, whole tissues, or any other substances susceptible to damage caused by chemical reactivity or time are preserved by cooling to sub-zero temperatures. At low enough temperatures, any enzymatic or chemical activity which might cause damage to the material in question is effectively stopped. Cryopreservation methods seek to reach low temperatures without causing additional damage caused by the formation of ice during freezing. Traditional cryopreservation has relied on coating the material to be frozen with a class of molecules termed cryoprotectants. New methods are constantly being investigated due to the inherent toxicity of many cryoprotectants. By default it should be considered that Cryopreservation alters/compromises the structure and function of cells unless it is proven otherwise for a particular cell population. Tissue and fluid preservation, also known as biobanking, biorepository science, or cryopreservation often referred to as cryobanking has become mainstream and big business. According to research by the British Broadcasting Corporation, the global biobanking market in 2010 was over $140 billion dollars, with a projected 30% increase by the year 2015 towards fostering biobanking initiatives

 

Fertility Preservation

Fertility preservation is the effort to help cancer patients retain their fertility, or ability to procreate. Research into how cancer affects reproductive health and preservation options are growing, sparked in part by the increase in the survival rate of cancer patients. The main methods of fertility preservation are ovarian protection by GnRH agonists, cryopreservation of ovarian tissue, eggs or sperm, or of embryos after in vitro fertilization. The patient may also choose to use egg or sperm from a donor by third party reproduction rather than having biological children.

   We are proud to welcome you to the “Tissue Preservation and Biobanking Conference” in the beautiful city of Barcelona, Spain. July 20-22 2015. This international meeting will bring together some of the world leaders in many fields related to tissue preservation and biobanking to discuss developments in this field. The conference will include research in many of the diverse subjects ranging from those in Cancer and Microbiology through database challenges. Perhaps one of the biggest challenges will be to anticipate the future needs and application facing the Next Generation Biobanking.

I welcome you to this conference and look forward to your questions and ideas

Temple  F. Smith, PhD.
Prof. Emeritus Boston University
Organizing committee for Biobanking-2015 

Known for Smith-Waterman algorithm

ISCB Accomplishment by a Senior Scientist Award

Director of the BioMolecular Engineering Research Center at Boston University (1991-2009)

Co-organizer, 1999 Institute for the Academic Advancement of Youth Discovering Biotechnology Day (1999)

Co-Founder and Chief Information Officer, Modular Genetics, Inc. (2000) 

 

 

The global Biobank market was USD 142.million in 2011 and it is forecasted that this market will reach USD 216.3 million in 2018 with compound annual growth rate of 54% from 2011-2018. This market witnessed an increased trend of mergers and acquisitions, leading to collaboration of public and private banks. This market is also facing challenges due to lack of standardized and quality biospecimens. The private sector biobanks market was USD.42.4.million in 2010 and it is projected to reach USD 93.7 million in 2018. The U.S and Europe have the largest market size for biobanks. Europe is the largest bio repositories market due to huge demand from Netherlands, Italy, Spain, Germany and several other countries. The Europe biobank market was valued as a USD 57.72 million market in 2014 and it is expected to reach $77.94 million USD by 2019with a CAGR of 6.19%.